China Medicine Stock Price To Book
| CHME Stock | USD 0.0002 0.00 0.00% |
China Medicine fundamentals help investors to digest information that contributes to China Medicine's financial success or failures. It also enables traders to predict the movement of China Pink Sheet. The fundamental analysis module provides a way to measure China Medicine's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to China Medicine pink sheet.
China |
China Medicine Company Price To Book Analysis
China Medicine's Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Current China Medicine Price To Book | 0.07 X |
Most of China Medicine's fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, China Medicine is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
| Competition |
Based on the latest financial disclosure, China Medicine has a Price To Book of 0.0733 times. This is 99.71% lower than that of the Pharmaceuticals sector and 97.01% lower than that of the Health Care industry. The price to book for all United States stocks is 99.23% higher than that of the company.
China Price To Book Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses China Medicine's direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of China Medicine could also be used in its relative valuation, which is a method of valuing China Medicine by comparing valuation metrics of similar companies.China Medicine is currently under evaluation in price to book category among its peers.
China Fundamentals
| Return On Equity | 0.0663 | |||
| Return On Asset | 0.0782 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | 0.18 % | |||
| Current Valuation | 2 M | |||
| Shares Outstanding | 23.71 M | |||
| Price To Earning | (6.67) X | |||
| Price To Book | 0.07 X | |||
| Price To Sales | 0.01 X | |||
| Revenue | 64.75 M | |||
| Gross Profit | 18.98 M | |||
| EBITDA | 13.41 M | |||
| Net Income | 1.72 M | |||
| Cash And Equivalents | 7.85 M | |||
| Cash Per Share | 0.20 X | |||
| Total Debt | 4.05 M | |||
| Debt To Equity | 0.03 % | |||
| Current Ratio | 11.15 X | |||
| Book Value Per Share | 1.97 X | |||
| Cash Flow From Operations | 16.96 M | |||
| Earnings Per Share | (0.01) X | |||
| Number Of Employees | 281 | |||
| Beta | 36.82 | |||
| Market Capitalization | 284.54 K | |||
| Total Asset | 66.84 M | |||
| Retained Earnings | 24.76 M | |||
| Working Capital | 85.75 M | |||
| Current Asset | 94.2 M | |||
| Current Liabilities | 8.45 M | |||
| Z Score | 1.2 | |||
| Net Asset | 66.84 M |
About China Medicine Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze China Medicine's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of China Medicine using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of China Medicine based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in China Pink Sheet
China Medicine financial ratios help investors to determine whether China Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in China with respect to the benefits of owning China Medicine security.